Skip to main content
Caplight Logo









Neurophyxia B.V.

Neurophyxia B.V.

Private
's-HertogenboschHealthcare & Life Scienceshttps://www.neurophyxia.com/

Last Round

Seed

Apr 20, 2008

Company Overview

Neurophyxia B.V. operates in Healthcare & Life Sciences and is based in 's-Hertogenbosch. Its latest recorded funding round was a Seed round in April 2008.

Neurophyxia B.V. is a clinical-stage biotechnology company that develops novel neuroprotective drugs to reduce brain cell injury caused by oxygen shortage in conditions such as stroke, cardiac arrest, and birth asphyxia.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Neurophyxia B.V. Comparables

Compare Neurophyxia B.V. with similar companies based on industry and business-model similarity.

Neurophyxia B.V. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Avilex Pharma
83%
veriNOS pharmaceuticals
82%
ZZ Biotech
79%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Neurophyxia B.V. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedApr 20, 2008
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 20, 2008

    Completed a Seed funding round.

Book a demo to see all signals

For institutional investors. Book with your work email.

Neurophyxia B.V. Filings

Explore SEC and related filing metadata, where available.

Neurophyxia B.V. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Neurophyxia B.V.'s valuation, stock price, and market status.

Is Neurophyxia B.V. a public or private company?

Neurophyxia B.V. is a private company.

What is the current stock price of Neurophyxia B.V.?

Neurophyxia B.V. is a private company, so its shares have no public market price. Caplight tracks Neurophyxia B.V.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Neurophyxia B.V. worth (valuation)?

Valuation information for Neurophyxia B.V. is not publicly available.

Can I buy Neurophyxia B.V. stock?

Neurophyxia B.V. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Neurophyxia B.V.'s last funding round?

Neurophyxia B.V.'s most recent funding round was Seed on April 20, 2008.

Who are the main investors in Neurophyxia B.V.?

Investor information for Neurophyxia B.V. is not publicly disclosed.

Will Neurophyxia B.V. IPO soon?

No public IPO plans have been announced for Neurophyxia B.V..

How can I track Neurophyxia B.V. secondary market activity?

Caplight tracks bids, offers, and trades in Neurophyxia B.V.'s shares on secondary markets.

Firmographic Details

Headquarters's-Hertogenbosch
Employee Range1
Year Founded2008
Last FundingApr 20, 2008

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?